Video

Dr. Toni Choueiri on Cabozantinib Versus Everolimus in Renal Cell Carcinoma

Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology Director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the METEOR trial in advanced renal cell carcinoma (RCC).

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the phase III METEOR trial that assessed cabozantinib for patients with advanced renal cell carcinoma (RCC).

The open-label phase III trial looked at cabozantinib, which inhibits multiple tyrosine kinases, including MET, VEGFRs, and AXL, compared with everolimus, a current standard of care, in 658 pretreated patients with RCC. Cabozantinib was investigated because VEGFR-resistance is common in RCC, making a novel VEGFR-inhibitor an unmet need, says Choueiri.

The primary endpoint of the trial was progression-free survival (PFS). The study found a 42% reduction in the risk of death or progression with cabozantinib compared to everolimus. The estimated median PFS among the first 375 randomized patients was 7.4 months with cabozantinib compared with 3.8 months for patients receiving everolimus (HR, 0.58; 95% CI, 0.45-0.75; P <.001).

<<<

View more from the 2015 European Cancer Congress

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Alberto Montero, MD, MBA, CPHQ